Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.
Overview
- Department of Neurosurgery, Ziyang Central Hospital, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang, China
- Outpatient Department, Ziyang Central Hospital, West China Hospital of Sichuan University-Ziyang Hospital, Ziyang, China
Abstract
Background: Glioblastoma (GBM) remains a lethal brain tumor with limited therapeutic options and near-universal recurrence. Drug repurposing offers a practical strategy, but pleiotropic compounds require systematic target triage to yield actionable and testable vulnerabilities.
Methods: We integrated GBM transcriptomic dysregulation with curated chlorpromazine (CPZ)-associated targets to define drug–disease intersecting genes, constructed a protein–protein interaction network, and developed an outcome-linked Lasso–Cox prognostic model to prioritize core candidates. Structure-informed docking and coarse-grained conformational sampling were used to evaluate the plausibility of a TTC23–CPZ interaction. TTC23-associated pathway activity, oncogenic state features, and immune contexture were characterized using expression stratification, enrichment and state scoring, cancer–immunity cycle analysis, and immune infiltration estimation. Functional validation was performed in GBM cell models to assess migration, apoptosis, cell viability, and clonogenic potential under TTC23 perturbation with or without CPZ exposure.
Results: Integrated CPZ–GBM intersection analysis and network-based prognostic modeling consistently prioritized TTC23 as a clinically relevant candidate. Structure-based analyses supported a consistent TTC23–CPZ interaction hypothesis across conformational sampling. Elevated TTC23 expression was associated with coordinated pathway activation, malignant functional states, and distinct immune-associated features. Functionally, TTC23 depletion suppressed migratory capacity, increased apoptotic susceptibility, reduced short-term viability, and impaired long-term clonogenic survival, while sensitizing GBM cells to CPZ-associated anti-tumor phenotypes.
Conclusion: Our multi-layer framework nominates TTC23 as a functionally relevant determinant associated with CPZ response in GBM and supports the CPZ–TTC23 axis as a candidate for biomarker-informed drug repurposing.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE4290, at NCBI GEO; found in “Data availability statement”
Data availability statement
The datasets analyzed in this study are publicly available. Bulk transcriptomic data were obtained from the Gene Expression Omnibus (GEO) under accession number GSE4290 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 6 authors, 7 keywords, 65 references, 3 RRIDs.
Cite
This paper
Hao, J., Liu, H., Ye, Y., Lv, J., Xue, F., & Cai, Y. (2026). Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma. Frontiers in pharmacology, 17, 1797067. https://
BibTeX
@article{hao2026network,
author = {Hao, Jianqiang and Liu, Hongbin and Ye, Yongqiang and Lv, Jianwei and Xue, Fang and Cai, Yanli},
title = {{Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma}},
journal = {Frontiers in pharmacology},
year = {2026},
month = may,
volume = {17},
pages = {1797067},
publisher = {Frontiers Media SA},
issn = {1663-9812},
doi = {10.3389/
url = {https://
pmid = {42158948},
pmcid = {PMC13181239}
}
RIS
TY - JOUR
AU - Hao, Jianqiang
AU - Liu, Hongbin
AU - Ye, Yongqiang
AU - Lv, Jianwei
AU - Xue, Fang
AU - Cai, Yanli
TI - Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma
T2 - Frontiers in pharmacology
J2 - Front Pharmacol
PY - 2026
DA - 2026/
VL - 17
SP - 1797067
SN - 1663-9812
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma",
"container-title": "Frontiers in pharmacology",
"author": [
{
"family": "Hao",
"given": "Jianqiang"
},
{
"family": "Liu",
"given": "Hongbin"
},
{
"family": "Ye",
"given": "Yongqiang"
},
{
"family": "Lv",
"given": "Jianwei"
},
{
"family": "Xue",
"given": "Fang"
},
{
"family": "Cai",
"given": "Yanli"
}
],
"container-title-short":
"volume": "17",
"page": "1797067",
"DOI": "10.3389/
"PMID": "42158948",
"PMCID": "PMC13181239",
"ISSN": "1663-9812",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
4
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3390/ijms26051875
- Identification of Prognostic Genes Related to Cell Senescence and Lipid Metabolism in Glioblastoma Based on Transcriptome and Single-Cell RNA-Seq Data.Journal: International journal of molecular sciencesIn common: other condition, 7 references
- [2] doi:10.1155/2022/8972730
- Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.Journal: Journal of immunology researchIn common: NCBI GEO GSE4290, clinical / translational, other condition, 3 references
- [3] doi:10.7150/jca.117209
- Robust machine-learning based prognostic index using fatty acid metabolism genes predicts prognosis and therapy responses in glioblastoma.Journal: Journal of CancerIn common: clinical / translational, other condition, 6 references
- [4] doi:10.1038/s41598-026-43219-y
- Identification of NFE2L2 as a key biomarker associated with pyroptosis in gliomas through bioinformatics and experiments.Journal: Scientific reportsIn common: other condition, 7 references
- [5] doi:10.1038/s41598-024-61515-3
- Identification of candidate biomarkers for GBM based on WGCNA.Journal: Scientific reportsIn common: NCBI GEO GSE4290, clinical / translational, other condition, 2 references
- [6] doi:10.4239/wjd.v15.i4.735
- Novel insights into immune-related genes associated with type 2 diabetes mellitus-related cognitive impairment.Journal: World journal of diabetesIn common: other condition, 7 references
- [7] doi:10.1016/j.isci.2026.115361
- Glioblastoma invasion into different organoid hosts reveals cell-intrinsic and proliferative migratory programs.Journal: iScienceIn common: other condition, 5 references
- [8] doi:10.1016/j.celrep.2024.115149 [code]
- Single-nucleus and spatial landscape of the sub-ventricular zone in human glioblastoma.Journal: Cell reportsIn common: other condition, 5 references
- [9] doi:10.1080/21655979.2021.1972197
- CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.Journal: BioengineeredIn common: NCBI GEO GSE4290, other condition, 2 references
- [10] doi:10.1002/brb3.3358
- Identification and validation of cortisol-related hub biomarkers and the related pathogenesis of biomarkers in Ischemic Stroke.Journal: Brain and behaviorIn common: 7 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
